+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
15 May 2017

DRL launches generic sofosbuvir & velpatasvir tablets for HCV in India

Dr Reddy’s Laboratories has launched the generic version of sofosbuvir 400mg and velpatasvir 100mg fixed-dose combination, indicated for the treatment of chronic hepatitis C, under a brand name Resof Total, in India.

Dr Reddy’s Resof Total tablets are available in bottle count size of 28.

Resof Total is used for the treatment of adult patients with chronic hepatitis C virus, genotype 1,2,3,4,5 or 6 infection  – without Cirrhosis or with compensated cirrhosis;  – with decompensated cirrhosis for use in combination with Ribavirin.

The sofosbuvir 400mg and velpatasvir 100mg fixed-dose combination is a generic version of Gilead’s brand Epclusa. treatment with this combination achieves a cure rate of more than 90% in all genotypes of hepatitis C virus (1,23,4, or 6). Achievement of higher cure rate with this combination in hepatitis C genotype 3 addresses a significant unmet need, since infection with genotype 3 of hepatitis C is upto 70% in Indian patients infected with hepatitis C.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.